Hemophilia pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(48 intermediate revisions by 2 users not shown)
Line 1: Line 1:


__NOTOC__
__NOTOC__
<div style="-webkit-user-select: none;">
{| class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;"
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=nkC1vZaUpxs|350}}
|-
|}
{{Hemophilia}}
{{Hemophilia}}
{{CMG}};{{AE}} {{Simrat}}
{{CMG}};{{AE}} {{Sab}}{{FNY}}


==Overview==
==Overview==
Hemophilia is a genetic bleeding disorder resulting from the insufficient levels of clotting factors in the body. The clotting factors irregularity causes a lack of clumping of blood required to form a clot to plug a site of a wound. The [[genes]] involved in the pathogenesis of hemophilia include the'' F8 ''[[gene]] in hemophilia A and'' F9'' [[gene]] in hemophilia B and C. Hemophilia predominantly affects the male population but the sub-type hemophilia C, with an autosomal inheritance pattern, can affect the males as well as females.
Hemophilia is a [[Genetic disorder|genetic bleeding disorder]] resulting from the insufficient levels of [[Coagulation|clotting factors]] in the [[Human body|body]]. The [[Coagulation|clotting factors]] irregularity causes a lack of [[Coagulation|clumping of blood]] required to form a [[Thrombus|clot]] to plug a site of a [[wound]]. The [[genes]] involved in the [[pathogenesis]] of hemophilia include the'' F8 ''[[gene]] in [[hemophilia A]], '' F9'' [[gene]] in [[hemophilia B]], and ''F11'' [[gene]] in [[Hemophilia C|C]]. Hemophilia predominantly affects the male population but the sub-type [[hemophilia C]], with an [[Autosome|autosomal]] [[Heredity|inheritance]] pattern, can affect the males as well as females.


==Pathophysiology==
==Pathophysiology==
*Hemophilia is caused by a mutation or change, in one of the genes, that provides instructions for making the clotting factor proteins needed to form a blood clot. This change or mutation can prevent the clotting protein from working properly or to be missing altogether. These genes are located on the [[X chromosome]]. Males have one [[X ]] and one [[Y chromosome]] (XY) and females have two X chromosomes (XX). Males inherit the X chromosome from their mothers and the Y chromosome from their fathers. Females inherit one X chromosome from each parent.
===Physiology===
The normal [[physiology]] of [[hemostasis]] can be summarized as follows:
*[[Hemostasis]] is a tightly regulated process whereby the [[Human body|body]] maintains a [[Homeostasis|homeostatic]] balance to permit normal [[blood flow]], without [[thrombosis]] or [[bleeding]].<ref name="pmid19308889">{{cite journal |vauthors=Lippi G, Favaloro EJ, Franchini M, Guidi GC |title=Milestones and perspectives in coagulation and hemostasis |journal=Semin. Thromb. Hemost. |volume=35 |issue=1 |pages=9–22 |date=February 2009 |pmid=19308889 |doi=10.1055/s-0029-1214144 |url=}}</ref>
*The process of [[hemostasis]] involves a fine balance between the [[Coagulation|procoagulant]] and [[anticoagulant]] factors. It attempts to maintain [[blood flow]] within the [[vascular]] compartment and promotes the formation of [[Thrombus|blood clots]] following [[vascular injury]].<ref name="pmid17243907">{{cite journal |vauthors=Lippi G, Franchini M, Guidi GC |title=Diagnostic approach to inherited bleeding disorders |journal=Clin. Chem. Lab. Med. |volume=45 |issue=1 |pages=2–12 |date=2007 |pmid=17243907 |doi=10.1515/CCLM.2007.006 |url=}}</ref>
*It also enables repair after [[vascular injury]], promotes [[Blood vessel|vessel]] healing, and maintains [[Blood vessel|vessel]] integrity.
*[[Hemostasis]] can be divided into three phases
**Each phase is explained as follows:
'''1. Primary hemostasis'''
*[[Endothelium|Endothelial]] damage marks the beginning of this phase.<ref>{{cite book | last = Favaloro | first = Emmanuel | title = Hemostasis and thrombosis : methods and protocols | publisher = Humana Press Springer | location = New York | year = 2017 | isbn = 9781493971961 }}</ref>
*It involves [[platelet]] [[adhesion]], activation and [[aggregation]], to form a [[platelet]] plug at the [[injury]] site.
*Circulating [[Platelet|platelets]] and [[Endothelial|endothelial cells]], both provide the source of [[Von Willebrand factor|von Willebrand factor (VWF)]].
*[[Von Willebrand factor|Von Willebrand factor (VWF)]] has two main functions. First, it acts as a [[mediator]] in binding of [[Platelet|platelets]] to the sub-[[endothelium]]. Then it protects the circulating [[factor VIII]] from [[Proteolysis|proteolytic]] [[degradation]].<ref name="pmid16889557">{{cite journal |vauthors=Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB |title=Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor |journal=J. Thromb. Haemost. |volume=4 |issue=10 |pages=2103–14 |date=October 2006 |pmid=16889557 |doi=10.1111/j.1538-7836.2006.02146.x |url=}}</ref><ref name="pmid24338608">{{cite journal |vauthors=Yee A, Kretz CA |title=Von Willebrand factor: form for function |journal=Semin. Thromb. Hemost. |volume=40 |issue=1 |pages=17–27 |date=February 2014 |pmid=24338608 |doi=10.1055/s-0033-1363155 |url=}}</ref>
*The [[Endothelium|endothelial]] [[Cell (biology)|cells]], which normally promote [[Anticoagulant|anticoagulation]], switch from [[anticoagulant]] to [[Coagulation|procoagulant]] upon [[vascular injury]]. They promote [[platelet]] [[aggregation]] by releasing the contents of their [[Weibel-Palade body|Weibel-Palade bodies]] and hence leading to enhanced local concentrations of [[Von Willebrand factor|von Willebrand factor (VWF)]] and [[Tissue factor|tissue factor (TF)]].<ref>{{cite book | last = Favaloro | first = Emmanuel | title = Hemostasis and thrombosis : methods and protocols | publisher = Humana Press Springer | location = New York | year = 2017 | isbn = 9781493971961 }}</ref>
*The released [[Von Willebrand factor|von Willebrand factor (VWF)]] binds to the [[collagen]] on the exposed sub-[[Endothelium|endothelial]] surface, and is then utilized for [[platelet]] binding via the [[Glycoprotein Ib|glycoprotein Ib (GPIb) complex]].
*The [[Platelet|platelets]] release their [[Granule (cell biology)|granules]] after undergoing a shape change. This event marks the formation of a [[platelet]] plug.
'''2. Secondary hemostasis'''
*The main goal of [[secondary]] [[hemostasis]] is to stabilize the [[platelet]] plug.<ref>{{cite book | last = Favaloro | first = Emmanuel | title = Hemostasis and thrombosis : methods and protocols | publisher = Humana Press Springer | location = New York | year = 2017 | isbn = 9781493971961 }}</ref>
*It involves the activation of [[Coagulation|coagulation system]] and [[Coagulation|coagulation factors]] to eventually produce cross-linked [[fibrinogen]] [[Fibrin|(“fibrin”)]].
*The process of [[platelet]] plug stabilization has been always referred to as the “[[Coagulation|Coagulation cascade]]” which can be separated into the [[Coagulation|intrinsic]], [[Coagulation|extrinsic]], and [[Coagulation|common pathways]].
'''3. Fibrinolysis'''
*[[Fibrinolysis]] involves the process of [[Physiology|physiological]] [[lysis]] of the [[Thrombus|clot]], generated by the actions of primary and secondary hemostasis, to permit [[Tissue (biology)|tissue]] repair under the supervision and help of multiple [[Protein|proteins]].<ref name="pmid28253534">{{cite journal |vauthors=Kwaan H, Lisman T, Medcalf RL |title=Fibrinolysis: Biochemistry, Clinical Aspects, and Therapeutic Potential |journal=Semin. Thromb. Hemost. |volume=43 |issue=2 |pages=113–114 |date=March 2017 |pmid=28253534 |doi=10.1055/s-0036-1598000 |url=}}</ref>
====Cell-Based Model of Coagulation====
*The [[Cell (biology)|cell]]-based model of [[hemostasis]] basically says that [[blood]] has to be exposed to [[Cell (biology)|cells]] containing the [[Tissue factor|tissue factor (TF)]] for the initiation of the [[Coagulation|clotting process]].<ref name="Hoffman2003">{{cite journal|last1=Hoffman|first1=Maureane|title=A cell-based model of coagulation and the role of factor VIIa|journal=Blood Reviews|volume=17|year=2003|pages=S1–S5|issn=0268960X|doi=10.1016/S0268-960X(03)90000-2}}</ref>
*It better reflects true [[in vivo]] [[hemostasis]].
*The model proposes three overlapping phases of [[hemostasis]] which are explained as follows:
'''a. Initiation'''
*It occurs on the surface of the [[tissue factor]]-bearing [[Cell (biology)|cell]].
*[[Tissue factor]]-bearing cells such as the [[Fibroblast|fibroblasts]] bind to the surface of [[Platelet|platelets]] in an evolving [[thrombus]].<ref name="Hoffman2003">{{cite journal|last1=Hoffman|first1=Maureane|title=A cell-based model of coagulation and the role of factor VIIa|journal=Blood Reviews|volume=17|year=2003|pages=S1–S5|issn=0268960X|doi=10.1016/S0268-960X(03)90000-2}}</ref>
*[[Factor VII]] comes into direct contact with the [[tissue factor]]-bearing [[Vascular|extravascular]] [[Cell (biology)|cells]] during [[vascular injury]], and rapidly undergoes activation via the [[Coagulation|extrinsic pathway]].
*Effective initiation means bringing [[Factor VII|FVIIa]]/[[Tissue factor|TF]] activity into close proximity to the activated [[platelet]] surfaces.
'''b. Amplification'''
*It occurs on the surface of the [[Platelet|platelets]] as they get activated.<ref>{{cite book | last = Favaloro | first = Emmanuel | title = Hemostasis and thrombosis : methods and protocols | publisher = Humana Press Springer | location = New York | year = 2017 | isbn = 9781493971961 }}</ref>
*[[Platelet|Platelets]] adhere at the site of [[Endothelium|endothelial]] [[injury]] and get activated by [[thrombin]].
*[[Platelet]] activation is marked by the execution of the following processes:
:*The release of [[Platelet alpha-granule|alpha granules]] which contain [[Factor V]] and [[Von Willebrand factor|von Willebrand factor (VWF)]]
:*Binding to [[Blood proteins|plasma proteins]] including [[Von Willebrand factor|von Willebrand factor (VWF)]]
:*Promoting the assemblage of [[Coagulation|procoagulant]] complexes
:*Ensuring prompt [[thrombin]] generation.
'''c. Propagation'''
*Propagation occurs on the surface of activated [[Platelet|platelets]].<ref>{{cite book | last = Favaloro | first = Emmanuel | title = Hemostasis and thrombosis : methods and protocols | publisher = Humana Press Springer | location = New York | year = 2017 | isbn = 9781493971961 }}</ref>
*It involves the assembly of [[Tenase|“tenase”]] ([[Factor VII|FVIIa]] and [[Factor IX|FIXa]]/[[Factor VIII|FVIIIa]]) and [[Prothrombinase|“prothrombinase”]] ([[Factor X|FXa]]/[[Factor V|FVa]]) complexes on the [[platelet]] surface, thus allowing [[thrombin]] generation to take place on a large scale which is necessary to form a [[hemostatic]] [[fibrin]] clot.<ref name="pmid28804815">{{cite journal |vauthors=Bonar RA, Lippi G, Favaloro EJ |title=Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders |journal=Methods Mol. Biol. |volume=1646 |issue= |pages=3–27 |date=2017 |pmid=28804815 |doi=10.1007/978-1-4939-7196-1_1 |url=}}</ref>


*The X chromosome contains many genes that are not present on the Y chromosome. This means that males only have one copy of most of the genes on the X chromosome, whereas females have 2 copies. Thus, males can have a disease like hemophilia if they inherit an affected X chromosome that has a mutation in either the [[factor VIII]] or [[factor IX]] gene. Females can also have hemophilia, but this is much rarer. In such cases both X chromosomes are affected or one is affected and the other is missing or inactive. In these females, bleeding symptoms may be similar to males with hemophilia.
===Pathogenesis===
*Hemophilia is an [[Sex linkage|X-linked]] [[bleeding]] disorder caused by a [[deficiency]] or complete absence of [[Factor VIII|coagulation factor VIII]] (hemophilia A) or [[factor IX]] (hemophilia B).<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref>
*[[Bleeding]] in hemophilia occurs due to the failure of [[Coagulation|secondary hemostasis]].<ref name="Bolton-MaggsPasi2003">{{cite journal|last1=Bolton-Maggs|first1=Paula HB|last2=Pasi|first2=K John|title=Haemophilias A and B|journal=The Lancet|volume=361|issue=9371|year=2003|pages=1801–1809|issn=01406736|doi=10.1016/S0140-6736(03)13405-8}}</ref>
*[[Coagulation|Primary hemostasis]] and the formation of [[platelet]] plug occurs normally but stabilization of the plug by [[fibrin]] is [[Defect|defective]] because of the [[generation]] of inadequate amounts of [[thrombin]].<ref name="Bolton-MaggsPasi2003">{{cite journal|last1=Bolton-Maggs|first1=Paula HB|last2=Pasi|first2=K John|title=Haemophilias A and B|journal=The Lancet|volume=361|issue=9371|year=2003|pages=1801–1809|issn=01406736|doi=10.1016/S0140-6736(03)13405-8}}</ref>
*[[Clinical]] expression of hemophilia usually correlates with the activity of the [[coagulation]] factor and the [[disease]] can be classified as:
:*Mild (factor level > 0.05–0.40 IU/mL)
:*Moderate (factor level = 0.01–0.05 IU/mL)
:*Severe (factor level < 0.01 IU/mL)
*Excessive [[bleeding]] in mild hemophilia [[Patient|patients]] occurs only after major injuries, [[surgery]], or other [[Invasive (medical)|invasive]] [[Surgery|procedures]].<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref>
*In [[Patient|patients]] with moderate hemophilia, [[Hemarthrosis|hemarthroses]] and muscle [[Hematoma|hematomas]] may occur after relatively minor [[Injury|injuries]].<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref>
*[[Bleeding]] occurs frequently and spontaneously in [[Patient|patients]] with severe hemophilia and this group can rarely also experience life-threatening episodes such as [[Retroperitoneum|retroperitoneal]] and [[Intracranial hemorrhage|intracranial bleeds]].<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref><ref name="pmid22456059">{{cite journal |vauthors=Berntorp E, Shapiro AD |title=Modern haemophilia care |journal=Lancet |volume=379 |issue=9824 |pages=1447–56 |date=April 2012 |pmid=22456059 |doi=10.1016/S0140-6736(11)61139-2 |url=}}</ref>
*Peculiar [[pathology]] of the types of hemophilia is discussed below:


*A female with one affected X chromosome is a "carrier" of hemophilia. Sometimes a female who is a carrier can have symptoms of hemophilia. In addition, she can pass the affected X chromosome with the clotting factor gene mutation on to her children.  
====Hemophilia A====
*Hemophilia A is caused by an absence or deficiency of [[Factor VIII|factor VIII (FVIII) protein]] activity.<ref name="OldenburgEl-Maarri2006">{{cite journal|last1=Oldenburg|first1=Johannes|last2=El-Maarri|first2=Osman|title=New Insight into the Molecular Basis of Hemophilia A|journal=International Journal of Hematology|volume=83|issue=2|year=2006|pages=96–102|issn=0925-5710|doi=10.1532/IJH97.06012}}</ref>
*It is a lifetime [[disease]] that is [[Transmittance|transmitted]] from usually asymptomatic carrier females to their male offspring.<ref name="OldenburgEl-Maarri2006">{{cite journal|last1=Oldenburg|first1=Johannes|last2=El-Maarri|first2=Osman|title=New Insight into the Molecular Basis of Hemophilia A|journal=International Journal of Hematology|volume=83|issue=2|year=2006|pages=96–102|issn=0925-5710|doi=10.1532/IJH97.06012}}</ref>
*Hemophilia A is characterized by recurrent [[bleeding]], in particular into [[Joint|joints]].<ref name="Bolton-MaggsPasi2003">{{cite journal|last1=Bolton-Maggs|first1=Paula HB|last2=Pasi|first2=K John|title=Haemophilias A and B|journal=The Lancet|volume=361|issue=9371|year=2003|pages=1801–1809|issn=01406736|doi=10.1016/S0140-6736(03)13405-8}}</ref>
*The recurrent [[bleeding]] in [[Joint|joints]] leads almost inevitably to severe [[arthropathy]].<ref name="pmid16684006">{{cite journal |vauthors=Roosendaal G, Lafeber FP |title=Pathogenesis of haemophilic arthropathy |journal=Haemophilia |volume=12 Suppl 3 |issue= |pages=117–21 |date=July 2006 |pmid=16684006 |doi=10.1111/j.1365-2516.2006.01268.x |url=}}</ref>
*The [[Molecule|molecular]] causes of [[Factor VIII|FVIII]] [[deficiency]] can be divided into 3 main categories:
#Classic [[Mutation|mutations]] in the ''F8'' [[gene]] that cause structural changes in the [[Factor VIII|FVIII]] [[molecule]] or even produce a truncated [[protein]] lacking essential functional [[Protein domains|domains]].<ref name="pmid9020152">{{cite journal |vauthors=Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ |title=Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins |journal=J. Biol. Chem. |volume=272 |issue=7 |pages=4327–34 |date=February 1997 |pmid=9020152 |doi= |url=}}</ref><ref name="pmid9525969">{{cite journal |vauthors=Pipe SW, Morris JA, Shah J, Kaufman RJ |title=Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin |journal=J. Biol. Chem. |volume=273 |issue=14 |pages=8537–44 |date=April 1998 |pmid=9525969 |doi= |url=}}</ref>
#[[Mutation|Mutations]] in [[Protein|proteins]] that interact [[Intracellular|intracellularly]] in the correct [[Protein folding|folding]] and trafficking of the [[Factor VIII|FVIII]] protein or [[Mutation|mutations]] in [[extracellular]] [[Blood plasma|plasma]] proteins such as [[Von Willebrand factor|von Willebrand factor (VWF)]].<ref name="pmid9546392">{{cite journal |vauthors=Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D |title=Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII |journal=Cell |volume=93 |issue=1 |pages=61–70 |date=April 1998 |pmid=9546392 |doi= |url=}}</ref><ref name="pmid12717434">{{cite journal |vauthors=Zhang B, Cunningham MA, Nichols WC, Bernat JA, Seligsohn U, Pipe SW, McVey JH, Schulte-Overberg U, de Bosch NB, Ruiz-Saez A, White GC, Tuddenham EG, Kaufman RJ, Ginsburg D |title=Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex |journal=Nat. Genet. |volume=34 |issue=2 |pages=220–5 |date=June 2003 |pmid=12717434 |doi=10.1038/ng1153 |url=}}</ref><ref name="pmid2506947">{{cite journal |vauthors=Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D |title=New variant of von Willebrand disease with defective binding to factor VIII |journal=Blood |volume=74 |issue=5 |pages=1591–9 |date=October 1989 |pmid=2506947 |doi= |url=}}</ref><ref name="pmid1832934">{{cite journal |vauthors=Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C |title=Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease |journal=Br. J. Haematol. |volume=78 |issue=4 |pages=506–14 |date=August 1991 |pmid=1832934 |doi= |url=}}</ref>
#The third category encompasses [[Patient|patients]] who have the clinical [[disease]] but have no [[Mutation|mutations]] in the ''F8'' [[gene]] or in any of the known interacting partners.<ref name="OldenburgEl-Maarri2006">{{cite journal|last1=Oldenburg|first1=Johannes|last2=El-Maarri|first2=Osman|title=New Insight into the Molecular Basis of Hemophilia A|journal=International Journal of Hematology|volume=83|issue=2|year=2006|pages=96–102|issn=0925-5710|doi=10.1532/IJH97.06012}}</ref>
*Less than 1/3 of the [[Patient|patients]] (mostly [[Old age|elderly]] with [[Comorbidity|comorbidities]]) of hemophilia develop [[Autoantibody|autoantibodies]] (inhibitors) against [[Factor VIII|factor VIII (FVIII)]] that can lead to spontaneous and severe [[bleeding]].<ref name="pmid28470674">{{cite journal |vauthors=Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM |title=Acquired hemophilia A: Updated review of evidence and treatment guidance |journal=Am. J. Hematol. |volume=92 |issue=7 |pages=695–705 |date=July 2017 |pmid=28470674 |doi=10.1002/ajh.24777 |url=}}</ref><ref name="pmid30562791">{{cite journal |vauthors=Yang F, Zhou YS, Jia Y |title=[Systemic lupus erythematosus with acquired hemophilia A: a case report] |language=Chinese |journal=Beijing Da Xue Xue Bao |volume=50 |issue=6 |pages=1108–1111 |date=December 2018 |pmid=30562791 |doi= |url=}}</ref>


*Even though hemophilia runs in families, some families have no prior history of family members with hemophilia. Sometimes, there are carrier females in the family, but no affected boys, just by chance. However, about one-third of the time, the baby with hemophilia is the first one in the family to be affected with a [[mutation]] in the [[gene]] for the clotting factor.<ref>{{Cite web | title =CDC Hemophilia Pathophysiology| url =http://www.cdc.gov/ncbddd/hemophilia/facts.html }}</ref>
====Hemophilia B====
*Hemophilia B is an [[Sex linkage|X-linked]] bleeding disorder caused by the [[deficiency]] of [[Factor IX|factor IX (FIX)]].<ref name="CastamanBonetti2013">{{cite journal|last1=Castaman|first1=G.|last2=Bonetti|first2=E.|last3=Messina|first3=M.|last4=Morfini|first4=M.|last5=Rocino|first5=A.|last6=Scaraggi|first6=F. A.|last7=Tagariello|first7=G.|title=Inhibitors in haemophilia B: the Italian experience|journal=Haemophilia|volume=19|issue=5|year=2013|pages=686–690|issn=13518216|doi=10.1111/hae.12158}}</ref>
*[[Factor IX]] is a [[vitamin K]]–dependent [[Blood plasma|plasma]] [[protease]] that plays a role in the [[Coagulation|intrinsic pathway]] of [[hemostasis]] and whose function is to cleave and activate [[Factor X]].<ref name="pmid25851415">{{cite journal |vauthors=Goodeve AC |title=Hemophilia B: molecular pathogenesis and mutation analysis |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1184–95 |date=July 2015 |pmid=25851415 |pmc=4496316 |doi=10.1111/jth.12958 |url=}}</ref>
*[[Bleeding]] tendency in hemophilia B is in good accordance with the severity of factor [[deficiency]].<ref name="pmid19515028">{{cite journal |vauthors=Chitlur M, Warrier I, Rajpurkar M, Lusher JM |title=Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) |journal=Haemophilia |volume=15 |issue=5 |pages=1027–31 |date=September 2009 |pmid=19515028 |doi=10.1111/j.1365-2516.2009.02039.x |url=}}</ref>
*[[Patient|Patients]] with the severe form ([[Factor IX]] <1%), a significant proportion of 30 to 45% of all affected by hemophilia B, usually suffer from recurrent [[joint]], [[Soft tissue|soft-tissue]], and [[muscle]] [[Bleeding|bleeds]].<ref name="pmid19515028">{{cite journal |vauthors=Chitlur M, Warrier I, Rajpurkar M, Lusher JM |title=Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) |journal=Haemophilia |volume=15 |issue=5 |pages=1027–31 |date=September 2009 |pmid=19515028 |doi=10.1111/j.1365-2516.2009.02039.x |url=}}</ref>
====Hemophilia C====
*Hemophilia C is an [[autosomal]] [[genetic disorder]] involving a lack of functional [[factor XI|clotting factor XI]].<ref name="pmid23610841">{{cite journal |vauthors=Shearin-Patterson T, Davidson E |title=Hemophilia C |journal=JAAPA |volume=26 |issue=4 |pages=50 |date=April 2013 |pmid=23610841 |doi= |url=}}</ref>
*This condition is not completely [[recessive]], as [[heterozygous]] individuals also show increased [[bleeding]].<ref name="pmid23610841">{{cite journal |vauthors=Shearin-Patterson T, Davidson E |title=Hemophilia C |journal=JAAPA |volume=26 |issue=4 |pages=50 |date=April 2013 |pmid=23610841 |doi= |url=}}</ref>
*The [[bleeding]] diathesis in hemophilia C is considerably milder than in hemophilia A or B.<ref name="pmid23929304">{{cite journal |vauthors=Duga S, Salomon O |title=Congenital factor XI deficiency: an update |journal=Semin. Thromb. Hemost. |volume=39 |issue=6 |pages=621–31 |date=September 2013 |pmid=23929304 |doi=10.1055/s-0033-1353420 |url=}}</ref><ref name="pmid20008187">{{cite journal |vauthors=Bolton-Maggs PH |title=Factor XI deficiency--resolving the enigma? |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=97–105 |date=2009 |pmid=20008187 |doi=10.1182/asheducation-2009.1.97 |url=}}</ref>
*The spontaneous [[soft tissue]] [[Bleeding|bleeds]] and [[Hemarthrosis|hemarthroses]] characteristic of hemophilia A and B are not features of hemophilia C.<ref name="pmid27216469">{{cite journal |vauthors=Wheeler AP, Gailani D |title=Why factor XI deficiency is a clinical concern |journal=Expert Rev Hematol |volume=9 |issue=7 |pages=629–37 |date=July 2016 |pmid=27216469 |doi=10.1080/17474086.2016.1191944 |url=}}</ref>
*[[Menorrhagia]] and [[epistaxis]] are the most common [[bleeding]] episodes encountered in hemophilia C.<ref name="pmid9883805">{{cite journal |vauthors=Kadir RA, Economides DL, Lee CA |title=Factor XI deficiency in women |journal=Am. J. Hematol. |volume=60 |issue=1 |pages=48–54 |date=January 1999 |pmid=9883805 |doi= |url=}}</ref>
*[[Factor XI]] [[deficiency]] can especially be a problem when [[Physical trauma|trauma]] involves the [[Mouth|oral]] and [[Nasal cavity|nasal cavities]] or the [[Urinary system|urinary tract]].<ref name="pmid23929304">{{cite journal |vauthors=Duga S, Salomon O |title=Congenital factor XI deficiency: an update |journal=Semin. Thromb. Hemost. |volume=39 |issue=6 |pages=621–31 |date=September 2013 |pmid=23929304 |doi=10.1055/s-0033-1353420 |url=}}</ref><ref name="pmid2052060">{{cite journal |vauthors=Asakai R, Chung DW, Davie EW, Seligsohn U |title=Factor XI deficiency in Ashkenazi Jews in Israel |journal=N. Engl. J. Med. |volume=325 |issue=3 |pages=153–8 |date=July 1991 |pmid=2052060 |doi=10.1056/NEJM199107183250303 |url=}}</ref>
*[[Symptom|Symptoms]] in hemophilia C [[Patient|patients]] correlate poorly with [[factor XI]] activity measured by [[Partial thromboplastin time|aPTT]]-based [[Assay|assays]].<ref name="pmid20008187">{{cite journal |vauthors=Bolton-Maggs PH |title=Factor XI deficiency--resolving the enigma? |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=97–105 |date=2009 |pmid=20008187 |doi=10.1182/asheducation-2009.1.97 |url=}}</ref><ref name="pmid25623511">{{cite journal |vauthors=Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, Bochicchio RA, Ferrara G, Guarini A, Foà R, Mazzucconi MG |title=Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre |journal=Haemophilia |volume=21 |issue=4 |pages=496–501 |date=July 2015 |pmid=25623511 |doi=10.1111/hae.12628 |url=}}</ref><ref name="pmid3871646">{{cite journal |vauthors=Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN |title=Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds |journal=Blood |volume=65 |issue=3 |pages=719–24 |date=March 1985 |pmid=3871646 |doi= |url=}}</ref><ref name="pmid7792729">{{cite journal |vauthors=Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG |title=Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study |journal=Thromb. Haemost. |volume=73 |issue=2 |pages=194–202 |date=February 1995 |pmid=7792729 |doi= |url=}}</ref>


==Genetics==
====Hemophilia A====
*Hemophilia A can be characterized by the detection of inversions of [[intron]] 22 (reported in 40–45% of severe [[Patient|patients]]) and [[intron]] 1 (reported in 1–6% of severe [[Patient|patients]]) of ''F8'' [[gene]] (which encodes [[factor VIII]]).<ref name="LakichKazazian1993">{{cite journal|last1=Lakich|first1=Delia|last2=Kazazian|first2=Haig H.|last3=Antonarakis|first3=Stylianos E.|last4=Gitschier|first4=Jane|title=Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A|journal=Nature Genetics|volume=5|issue=3|year=1993|pages=236–241|issn=1061-4036|doi=10.1038/ng1193-236}}</ref><ref name="Bagnall2002">{{cite journal|last1=Bagnall|first1=R. D.|title=Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A|journal=Blood|volume=99|issue=1|year=2002|pages=168–174|issn=00064971|doi=10.1182/blood.V99.1.168}}</ref>
*The ''F8'' [[gene]] is located on the X [[Chromosome (genetic algorithm)|chromosome]].<ref name="pmid6438525">{{cite journal |vauthors=Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM |title=Characterization of the human factor VIII gene |journal=Nature |volume=312 |issue=5992 |pages=326–30 |date=1984 |pmid=6438525 |doi= |url=}}</ref>
*[[Point mutation|Point mutations]] ([[Missense mutation|missense]], [[Nonsense mutation|nonsense]], and [[Splice site mutation|splice site mutations]]) account for 67% of [[Molecule|molecular]] [[Defect|defects]] described.
*Small insertions and deletions represent 25% of such [[Defect|defects]].<ref name="LannoyAbinet2009">{{cite journal|last1=Lannoy|first1=N.|last2=Abinet|first2=I.|last3=Dahan|first3=K.|last4=Hermans|first4=C.|title=Identification ofde novodeletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency|journal=Haemophilia|volume=15|issue=3|year=2009|pages=797–801|issn=13518216|doi=10.1111/j.1365-2516.2008.01974.x}}</ref>
*Roughly 6% of all [[Mutation|mutations]] are large deletions.<ref name="LannoyAbinet2009">{{cite journal|last1=Lannoy|first1=N.|last2=Abinet|first2=I.|last3=Dahan|first3=K.|last4=Hermans|first4=C.|title=Identification ofde novodeletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency|journal=Haemophilia|volume=15|issue=3|year=2009|pages=797–801|issn=13518216|doi=10.1111/j.1365-2516.2008.01974.x}}</ref>
====Hemophilia B====
*[[Missense mutation|Missense]], [[Nonsense mutation|nonsense]], and [[Splice site mutation|splice site mutations]] in the ''F9'' [[gene]] (which is located on the X chromosome and encodes [[factor XI]]) are the most common, accounting for around 70% of [[Mutation|mutations]].<ref name="PeyvandiGaragiola2016">{{cite journal|last1=Peyvandi|first1=Flora|last2=Garagiola|first2=Isabella|last3=Young|first3=Guy|title=The past and future of haemophilia: diagnosis, treatments, and its complications|journal=The Lancet|volume=388|issue=10040|year=2016|pages=187–197|issn=01406736|doi=10.1016/S0140-6736(15)01123-X}}</ref><ref name="pmid237463">{{cite journal |vauthors=Davie EW, Fujikawa K |title=Basic mechanisms in blood coagulation |journal=Annu. Rev. Biochem. |volume=44 |issue= |pages=799–829 |date=1975 |pmid=237463 |doi=10.1146/annurev.bi.44.070175.004055 |url=}}</ref><ref name="pmid2994716">{{cite journal |vauthors=Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K |title=Nucleotide sequence of the gene for human factor IX (antihemophilic factor B) |journal=Biochemistry |volume=24 |issue=14 |pages=3736–50 |date=July 1985 |pmid=2994716 |doi= |url=}}</ref>
*[[Frameshift mutation|Frameshift mutations]] in the F9 [[gene]] account for approximately 17%.<ref name="PeyvandiGaragiola2016">{{cite journal|last1=Peyvandi|first1=Flora|last2=Garagiola|first2=Isabella|last3=Young|first3=Guy|title=The past and future of haemophilia: diagnosis, treatments, and its complications|journal=The Lancet|volume=388|issue=10040|year=2016|pages=187–197|issn=01406736|doi=10.1016/S0140-6736(15)01123-X}}</ref>
*Large [[Deletion (genetics)|deletions]] and [[promoter region]] [[Mutation|mutations]] are relatively rare, accounting for 3% and 2% respectively.<ref name="PeyvandiGaragiola2016">{{cite journal|last1=Peyvandi|first1=Flora|last2=Garagiola|first2=Isabella|last3=Young|first3=Guy|title=The past and future of haemophilia: diagnosis, treatments, and its complications|journal=The Lancet|volume=388|issue=10040|year=2016|pages=187–197|issn=01406736|doi=10.1016/S0140-6736(15)01123-X}}</ref>


====Hemophilia C====
*Hemophilia C, characterized by a [[deficiency]] of [[factor XI]], results from [[Mutation|mutations]] ([[Splice site mutation|splice site]], [[Nonsense mutation|nonsense]], or [[missense mutation]]) in the F11 [[gene]].<ref name="pmid2813350">{{cite journal |vauthors=Asakai R, Chung DW, Ratnoff OD, Davie EW |title=Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=86 |issue=20 |pages=7667–71 |date=October 1989 |pmid=2813350 |pmc=298131 |doi= |url=}}</ref>
*[[Zygosity|Homozygous]] or [[Zygosity|compound heterozygous]] [[deficiency]] of [[factor XI]] results in a variable [[bleeding]] [[phenotype]] but the clinical presentation in [[Zygosity|heterozygotes]] is less predictable.<ref name="pmid25817556">{{cite journal |vauthors=Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J |title=Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study |journal=Haemophilia |volume=21 |issue=4 |pages=481–9 |date=July 2015 |pmid=25817556 |pmc=4657494 |doi=10.1111/hae.12655 |url=}}</ref>


Hemophilia – The hemophilias are bleeding disorders caused by deficiency of clotting factors:
==Associated Conditions==
*Hemophilia can be associated with the following conditions:
:*[[End stage liver failure|End-stage liver disease]]<ref name="pmid12176875">{{cite journal |vauthors=Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A |title=End-stage liver disease in persons with hemophilia and transfusion-associated infections |journal=Blood |volume=100 |issue=5 |pages=1584–9 |date=September 2002 |pmid=12176875 |doi= |url=}}</ref><ref name="pmid30278553">{{cite journal |vauthors=Qvigstad C, Tait RC, Rauchensteiner S, Berntorp E, de Moerloose P, Schutgens RE, Holme PA |title=The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment |journal=Medicine (Baltimore) |volume=97 |issue=39 |pages=e12551 |date=September 2018 |pmid=30278553 |pmc=6181599 |doi=10.1097/MD.0000000000012551 |url=}}</ref>
:*[[Autoimmunity|Autoimmune]] [[thyroiditis]]<ref name="pmid25547669">{{cite journal |vauthors=Pathirana UG, Gunawardena N, Abeysinghe H, Copley HC, Somarathne MG |title=Acquired haemophilia A associated with autoimmune thyroiditis: a case report |journal=J Med Case Rep |volume=8 |issue= |pages=469 |date=December 2014 |pmid=25547669 |pmc=4320580 |doi=10.1186/1752-1947-8-469 |url=}}</ref>
:*[[Autoimmune pancreatitis]]<ref name="pmid29582334">{{cite journal |vauthors=Narazaki T, Haji S, Nakashima Y, Tsukamoto Y, Tsuda M, Takamatsu A, Ohno H, Matsushima T, Matsumoto T, Nogami K, Shima M, Shiratsuchi M, Ogawa Y |title=Acquired hemophilia A associated with autoimmune pancreatitis with serum IgG4 elevation |journal=Int. J. Hematol. |volume=108 |issue=3 |pages=335–338 |date=September 2018 |pmid=29582334 |doi=10.1007/s12185-018-2441-3 |url=}}</ref>
:*[[Hematology|Hematologic]] [[Cancer|malignancies]]<ref name="pmid24750687">{{cite journal |vauthors=Mulliez SM, Vantilborgh A, Devreese KM |title=Acquired hemophilia: a case report and review of the literature |journal=Int J Lab Hematol |volume=36 |issue=3 |pages=398–407 |date=June 2014 |pmid=24750687 |doi=10.1111/ijlh.12210 |url=}}</ref>
:*[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]<ref name="pmid26754251">{{cite journal |vauthors=Shetty S, Sharma N, Ghosh K |title=Epidemiology of hepatocellular carcinoma (HCC) in hemophilia |journal=Crit. Rev. Oncol. Hematol. |volume=99 |issue= |pages=129–33 |date=March 2016 |pmid=26754251 |doi=10.1016/j.critrevonc.2015.12.009 |url=}}</ref>
:*[[Pregnancy]]<ref name="pmid28262242">{{cite journal |vauthors=Barg AA, Livnat T, Kenet G |title=An extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A |journal=Thromb. Res. |volume=151 Suppl 1 |issue= |pages=S82–S85 |date=March 2017 |pmid=28262242 |doi=10.1016/S0049-3848(17)30074-9 |url=}}</ref>
:*[[Polymyositis and dermatomyositis|Polymyositis]]<ref name="pmid30562791">{{cite journal |vauthors=Yang F, Zhou YS, Jia Y |title=[Systemic lupus erythematosus with acquired hemophilia A: a case report] |language=Chinese |journal=Beijing Da Xue Xue Bao |volume=50 |issue=6 |pages=1108–1111 |date=December 2018 |pmid=30562791 |doi= |url=}}</ref>
:*[[Autoimmune hemolytic anemia]]<ref name="pmid30562791">{{cite journal |vauthors=Yang F, Zhou YS, Jia Y |title=[Systemic lupus erythematosus with acquired hemophilia A: a case report] |language=Chinese |journal=Beijing Da Xue Xue Bao |volume=50 |issue=6 |pages=1108–1111 |date=December 2018 |pmid=30562791 |doi= |url=}}</ref>
:*[[Hepatitis A]], [[Hepatitis B|B]], and [[Hepatitis C|C]]<ref name="pmid28300362">{{cite journal |vauthors=Makris M, Konkle BA |title=Hepatitis C in haemophilia: time for treatment for all |journal=Haemophilia |volume=23 |issue=2 |pages=180–181 |date=March 2017 |pmid=28300362 |doi=10.1111/hae.13183 |url=}}</ref><ref name="pmid15009473">{{cite journal |vauthors=Kasper CK |title=AIDS, hepatitis and hemophilia |journal=J. Thromb. Haemost. |volume=2 |issue=3 |pages=516–8 |date=March 2004 |pmid=15009473 |doi= |url=}}</ref><ref>{{cite book | last = Goodman | first = Catherine | title = Pathology : implications for the physical therapist | publisher = Elsevier Saunders | location = St. Louis, Missouri | year = 2015 | isbn = 9781455745913 }}</ref><ref name="pmid28752601">{{cite journal |vauthors=Murphy N, O'Mahony B, Flanagan P, Noone D, White B, Bergin C, Norris S, Thornton L |title=Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era |journal=Haemophilia |volume=23 |issue=5 |pages=712–720 |date=September 2017 |pmid=28752601 |doi=10.1111/hae.13244 |url=}}</ref>
:*[[Osteoporosis]]<ref name="pmid26825623">{{cite journal |vauthors=Eldash HH, Atwa ZT, Saad MA |title=Vitamin D deficiency and osteoporosis in hemophilic children: an intermingled comorbidity |journal=Blood Coagul. Fibrinolysis |volume=28 |issue=1 |pages=14–18 |date=January 2017 |pmid=26825623 |doi=10.1097/MBC.0000000000000519 |url=}}</ref><ref name="pmid25485786">{{cite journal |vauthors=Albayrak C, Albayrak D |title=Vitamin D levels in children with severe hemophilia A: an underappreciated deficiency |journal=Blood Coagul. Fibrinolysis |volume=26 |issue=3 |pages=285–9 |date=April 2015 |pmid=25485786 |doi=10.1097/MBC.0000000000000237 |url=}}</ref>
:*[[Rheumatoid arthritis]]<ref name="pmid30562791">{{cite journal |vauthors=Yang F, Zhou YS, Jia Y |title=[Systemic lupus erythematosus with acquired hemophilia A: a case report] |language=Chinese |journal=Beijing Da Xue Xue Bao |volume=50 |issue=6 |pages=1108–1111 |date=December 2018 |pmid=30562791 |doi= |url=}}</ref>
:*[[Myasthenia gravis|Myasthenia Gravis]]<ref name="pmid23395131">{{cite journal |vauthors=Cano LM, Quesada H, García-Alhama J, Cardona P |title=[Acquired haemophilia associated to myasthenia gravis] |language=Spanish; Castilian |journal=Med Clin (Barc) |volume=141 |issue=4 |pages=185–6 |date=August 2013 |pmid=23395131 |doi=10.1016/j.medcli.2012.12.005 |url=}}</ref>
:*[[Systemic lupus erythematosus|Systemic lupus erythematosus (SLE)]]<ref name="pmid30562791">{{cite journal |vauthors=Yang F, Zhou YS, Jia Y |title=[Systemic lupus erythematosus with acquired hemophilia A: a case report] |language=Chinese |journal=Beijing Da Xue Xue Bao |volume=50 |issue=6 |pages=1108–1111 |date=December 2018 |pmid=30562791 |doi= |url=}}</ref>
:*[[Moyamoya disease|Moyamoya syndrome]]<ref name="pmid27638653">{{cite journal |vauthors=Saini AG, Goswami JN, Suthar R, Sankhyan N, Vyas S, Singhi P |title=Probable Moyamoya Syndrome in Association with Hemophilia A in an Infant |journal=Indian J Pediatr |volume=84 |issue=2 |pages=164–165 |date=February 2017 |pmid=27638653 |doi=10.1007/s12098-016-2229-5 |url=}}</ref>


•Deficiency of factor VIII (factor 8) – Hemophilia A
==Gross Pathology==
On [[gross pathology]], hemophilia is characterized by the following findings:
*[[Hemarthrosis|Hemarthroses]]<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref>
*[[Muscle]] [[Hematoma|hematomas]]<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref>
*[[Subcutaneous tissue|Subcutaneous]] [[bleeding]]<ref name="pmid23719140">{{cite journal |vauthors=Kimura H, Uegaki M, Aoyama T, Miyoshi T, Nagai K, Hashimura T |title=[Acquired hemophilia presenting as gross hematuria and perineal subcutaneous hemorrhage after prostate biopsy: a case report] |language=Japanese |journal=Hinyokika Kiyo |volume=59 |issue=5 |pages=305–8 |date=May 2013 |pmid=23719140 |doi= |url=}}</ref>
*[[Gross examination|Gross]] [[hematuria]]<ref name="pmid23719140">{{cite journal |vauthors=Kimura H, Uegaki M, Aoyama T, Miyoshi T, Nagai K, Hashimura T |title=[Acquired hemophilia presenting as gross hematuria and perineal subcutaneous hemorrhage after prostate biopsy: a case report] |language=Japanese |journal=Hinyokika Kiyo |volume=59 |issue=5 |pages=305–8 |date=May 2013 |pmid=23719140 |doi= |url=}}</ref>
*[[Limb (anatomy)|Extremity]] [[Edema|swelling]]<ref name="MaesakoShimomura2013">{{cite journal|last1=Maesako|first1=Yoshitomo|last2=Shimomura|first2=Daiki|last3=Ohno|first3=Hitoshi|title=Acquired hemophilia A|journal=Tenri Medical Bulletin|volume=16|issue=2|year=2013|pages=133–135|issn=1344-1817|doi=10.12936/tenrikiyo.16-015}}</ref>
*[[Epistaxis]]<ref name="pmid9883805">{{cite journal |vauthors=Kadir RA, Economides DL, Lee CA |title=Factor XI deficiency in women |journal=Am. J. Hematol. |volume=60 |issue=1 |pages=48–54 |date=January 1999 |pmid=9883805 |doi= |url=}}</ref>
*[[Menorrhagia]]<ref name="pmid9883805">{{cite journal |vauthors=Kadir RA, Economides DL, Lee CA |title=Factor XI deficiency in women |journal=Am. J. Hematol. |volume=60 |issue=1 |pages=48–54 |date=January 1999 |pmid=9883805 |doi= |url=}}</ref>
*Excessive uncontrollable [[bleeding]] after major/minor [[Injury|injuries]]<ref name="pmid11396445">{{cite journal |vauthors=Mannucci PM, Tuddenham EG |title=The hemophilias--from royal genes to gene therapy |journal=N. Engl. J. Med. |volume=344 |issue=23 |pages=1773–9 |date=June 2001 |pmid=11396445 |doi=10.1056/NEJM200106073442307 |url=}}</ref><ref name="pmid22456059">{{cite journal |vauthors=Berntorp E, Shapiro AD |title=Modern haemophilia care |journal=Lancet |volume=379 |issue=9824 |pages=1447–56 |date=April 2012 |pmid=22456059 |doi=10.1016/S0140-6736(11)61139-2 |url=}}</ref>
==Microscopic Pathology==
On [[microscopic]] [[Histopathology|histopathological]] [[analysis]], hemophilia can be characterized by the following findings:
*Reduced [[Red blood cell|red blood cell (RBC)]] count<ref>Centers for Disease Control and Prevention. Hemophilia Diagnosis. http://www.cdc.gov/ncbddd/hemophilia/diagnosis.html</ref>


•Deficiency of factor IX (factor 9) – Hemophilia B
Hemophilia A and B severity is classified according to the level of circulating factor activity, which correlates with bleeding risk and the risk of inhibitor development. Mild disease is defined as a factor activity level above 5 and below 40 percent; moderate disease is a factor activity level between 1 and 5 percent; and severe disease is a factor activity level below 1 percent [1]. (See "Clinical manifestations and diagnosis of hemophilia", section on 'Definitions'.)
Hemophilia C is sometimes used to refer to factor XI (factor 11) deficiency, but the phenotypic disease severity, type of bleeding manifestations, and management differ from hemophilia A and B. (See "Factor XI (eleven) deficiency".)
Acquired hemophilia refers to development of a clotting factor deficiency that was not present at birth. Typically, this occurs when an autoantibody is produced against an endogenous factor. Acquired hemophilia A (acquired inhibitor against endogenous factor VIII) is the most common. (See "Acquired inhibitors of coagulation".)
●Treatment – Previously untreated patients (PUPs) are those who have not received infusions of replacement factor. Previously treated patients (PTPs) are those who have been exposed to replacement factor.
●Exposure days – Exposure days refers to the number of days on which the individual was exposed to exogenous factor. As an example, an individual treated with factor infusions on Monday, Wednesday, and Friday for two weeks has six exposure days. An individual treated with two infusions of factor on Monday has one exposure day. The number of exposure days correlates with the risk of inhibitor development, but it is not necessarily a good surrogate for treatment intensity, as discussed below. (See 'Therapy considerations' below.)
●Inhibitors – An inhibitor is a neutralizing antibody that interferes with the function of the factor against which it is directed. In hemophilia A and B, inhibitors are alloantibodies directed against infused factor. Not all antibodies to factor act as inhibitors. Non-neutralizing antibodies directed against coagulation factors may be seen in individuals with hemophilia and in the general population [2].
•Titer – Inhibitor titers are quantified using the Bethesda assay. This is a clot-based assay in which serial dilutions of patient plasma are incubated with pooled normal plasma and residual clotting activity is measured. In many cases, the Nijmegen modification is used. Heat treatment is sometimes used to remove any exogenous factor VIII and more accurately determine the patient's true inhibitor titer. Individuals receiving emicizumab cannot have an inhibitor titer determined using a clot-based assay. A chromogenic Bethesda assay (CBA) is used for individuals receiving emicizumab.
The titer is the reciprocal of the dilution of patient plasma that results in 50 percent factor activity, expressed as Bethesda units (BU) or Nijmegen-Bethesda units (NBU). The titer may also be expressed in BU/mL. The greater the dilution required to titrate out the inhibitor, the higher the inhibitor titer.
•High- versus low-responding inhibitor – An inhibitor titer of ≥5 BU at any time is considered a high-responding inhibitor, and a persistent titer <5 BU despite repeated factor VIII exposure is considered a low-responding inhibitor [3,4]. Low-responding inhibitors do not rise to ≥5 BU with repeated exposure to factor. A patient whose titer is ≥5 BU has a greater likelihood of increase upon re-exposure to factor.
•Transient inhibitors – Inhibitors that disappear spontaneously (ie, decrease below the definition threshold within six months of initial documentation despite continuing exposure to factor) are referred to as transient inhibitors [1].
●Immune tolerance induction – Immune tolerance induction (ITI, also called immune tolerance therapy [ITT] or inhibitor eradication) is the primary method used to eliminate or control inhibitors. It involves administration of frequent, regularly scheduled doses of the deficient factor to reset (tolerize) the individual's immune system and reduce production of the antibody. The immunologic principles are somewhat similar to immunotherapy for allergic disease, although there are significant differences in the clinical manifestations of the immune response. (See "Allergen immunotherapy for allergic disease: Therapeutic mechanisms" and 'Immune tolerance induction' below.)
PATHOGENESIS
Mechanisms of formation and action — Inhibitors form when the immune system recognizes the infused factor as foreign and generates neutralizing antibodies. Predisposing and provoking factors are enumerated below. (See 'Predisposing influences' below.)
Inhibitors are high-affinity antibodies (primarily immunoglobulin G [IgG]) directed against the factor protein [5]. They are often polyclonal (ie, separate antibody specificities produced by separate B cell clones that recognize distinct epitopes). In contrast, inhibitors in individuals with acquired hemophilia are often monoclonal. In one study, approximately 80 percent of individuals with hemophilia A who developed inhibitors had at least two or more independent antibody specificities against factor VIII [6].
In hemophilia A, most antibodies are directed against the A2 and/or C2 domains of the protein. Mechanisms include the following:
●Interference with factor VIII binding to phospholipids or von Willebrand factor (VWF) via binding to the C2 domain [6-13]
●Interference with factor VIII binding to factor IX or blocking of the intrinsic ten-ase activity of the factor VIIIa-factor IXa complex [14,15]
●Increased clearance of factor VIII via direct proteolysis [16,17]
The domain structure of the factor VIII and factor IX molecules and functional regions of the proteins are discussed separately. (See "Biology and normal function of factor VIII and factor IX".)
Predisposing influences — Influences that contribute to inhibitor development are complex, multifactorial, and incompletely understood [3]. They are likely to involve characteristics of the patient (eg, variations in factor genes and immune regulatory genes, race), the environment (eg, surgery, trauma, or other danger signals), and the hemophilia treatment (eg, age at first exposure, product used, intensity of dosing, use of prophylaxis versus on-demand treatment).
Sometimes these elements may be difficult to tier in importance because most of the available data come from observational studies that may be subject to a variety of interrelated and confounding factors. As examples:
●Different populations in different parts of the world may have different factor and immune response genotypes and may be treated using different products at different intensities, starting at different ages
●Individuals with more severe disease are likely to have more exposure days earlier in their disease course
●Individuals in certain populations may co-inherit certain factor mutations and certain mutations affecting the immune response
Risk factors for inhibitor development in hemophilia A have been studied extensively compared with hemophilia B because hemophilia A is more common and the incidence of inhibitors is higher. Further, hemophilia B is often associated with point mutations, which are less commonly associated with inhibitor development, rather than deletions. The extent to which the information on predisposing factors can be generalized to hemophilia B is not known and may differ substantially. Research continues to define the best predictors of inhibitor development in both hemophilia A and B, as well as methods to decrease or prevent formation.
Patient characteristics — Inhibitors are much more common in hemophilia A than in hemophilia B. (See 'Epidemiology' below.)
Beyond this, there are several established patient characteristics that increase inhibitor risk. These include genetic factors related to the specific factor mutation and those related to immune response genes. Race and ethnicity also play a role, but their mechanisms are not well-elucidated.
●Factor variant – The factor mutation (variant) determines disease severity, and more severe disease is associated with greater inhibitor risk. This is likely because lower levels (or absence) of endogenous factor will make it less likely that the individual's immune system was tolerized to the antigen during development and more likely that the infused product is recognized by the recipient's immune system as foreign. There may also be factor antigen circulating in some individuals with absent factor activity, and these individuals may be more likely to be tolerized to that factor.
Thus, large deletions and nonsense mutations (creation of an internal stop codon) in the F8 gene are much more likely to be associated with inhibitors compared with small deletions, insertions, or missense mutations (creation of an amino acid change) [3,18-22]. The intron 22 gene inversion, present in 40 to 45 percent of individuals with severe hemophilia A, carries an intermediate risk [21,23]. (See "Genetics of hemophilia A and B", section on 'Factor VIII (F8) gene/hemophilia A'.)
•In a meta-analysis of studies that examined F8 genotype and inhibitor risk in 5383 individuals with hemophilia A using intron 22 inversions as the control group, the odds ratios (ORs) for inhibitor development with large deletions, nonsense mutations, small deletions/insertions, and missense mutations were 3.6, 1.4, 0.5, and 0.3, respectively [23].
•In an analysis of 586 participants who had data entered in the Haemophilia A Mutation, Search, Test and Resource Site (HAMSTeRS registry), the frequencies of inhibitors were as follows [24]:
-Large (>200 bp) deletions – 38 percent
-Nonsense mutations – 36 percent
-Inversions – 20 percent
-Small (≤86 bp) deletions – 14 percent
-Missense mutations – 7 percent
Other studies have identified specific high-risk F8 variants in individuals with mild to moderate hemophilia A such as the C2 domain Trp2229Cys mutation and the Arg593Cys mutation [25,26].
As noted below, there are several normal F8 polymorphisms that do not cause hemophilia and may be distributed differently in individuals of different races; these may contribute to different rates of inhibitor development (eg, due to minor antigenic differences between endogenous factor VIII and the factor VIII protein sequence in the replacement product) [27]. (See 'Replacement product' below.)
Data are much more limited for hemophilia B, but they confirm a greater frequency of inhibitors in those with severe disease [28]. In a sequencing study, complete F9 gene deletions conferred a higher risk than truncating mutations, partial deletions, or missense mutations [29].
●Immune response genes – Development of inhibitors is an immune phenomenon, and some data have suggested that genes involved in the immune response to foreign proteins may contribute to inhibitor development [3]. As an example, the Hemophilia Inhibitor Genetics Study (HIGS) evaluated genes involved in immune regulation among 104 sibling pairs with hemophilia A who were discordant in inhibitor status [30]. As siblings, these individuals had the same F8 mutation. Analysis of single nucleotide polymorphisms (SNPs) demonstrated variations in 13 immune response/immune modifier genes that correlated with inhibitor development. Other studies have implicated specific genes including those that encode human leukocyte antigen (HLA) class II antigens, interleukins, tumor necrosis factor (TNF)-alpha, and/or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) [31-36].
●Other genetic contributions – There may be other as yet undefined genetic factors that influence inhibitor development. This possibility is suggested by case-control studies that have found increased rates of inhibitors in individuals with a family history of inhibitors [19,25,37].
●Race – Individuals with African or Hispanic ancestry have a higher rate of inhibitor development compared with whites. A study from the Centers for Disease Control (CDC) in the United States that reported on the prevalence of inhibitors among 5651 people with hemophilia A found the following prevalence of inhibitors in different races [38]:
•Black – 27 percent
•Hispanic – 25 percent
•Non-Hispanic white – 16 percent
Other studies have reported significantly higher inhibitor prevalences in blacks and Asians with hemophilia A. As an example, a study involving 460 families in the Malmo international brother study (388 families with hemophilia A and 72 families with hemophilia B) reported inhibitors in 56 percent of blacks and 27 percent of whites [39]. The incidence of inhibitors in this study was as high as 50 percent in individuals with Asian, Indian, and Hispanic ancestry. In hemophilia B, a review from a large United States database (3800 patients) found that the OR for inhibitor development was 2.8 for blacks (95% CI 1.4-5.5) and 1.7 for Hispanics (95% CI 0.7-3.7) [28].
Race may be a surrogate for a number of biologic differences that affect the immune response and/or for differences in medical care.
As noted above, another connection between race and inhibitor development may involve mismatch between the amino acid sequence of the factor present in the replacement product and the endogenous factor in the recipient that could make the recipient's immune system more likely to recognize the replacement factor as foreign and generate an immune response. In a study that sequenced the F8 gene in 78 black people with hemophilia A who had developed inhibitors, the people with inhibitors were more likely to have endogenous factor VIII amino acid sequences that differed from the amino acid sequence in the recombinant factor VIII replacement products that were available at the time [27]. (See 'Replacement product' below.)
●Age – Age-associated changes in immune function may also affect inhibitor development. The risk is highest in children under the age of five years, and risk increases beyond the age of 60 years [40]. (See "Immune function in older adults".)
The correlation between age at which prophylaxis is initiated and risk of inhibitor development is complex, as discussed below. (See 'Therapy considerations' below.)
Many of these studies are affected by different frequency of inhibitor testing, making cross-study comparisons difficult.
Therapy considerations — Therapy-related factors that may influence inhibitor development in susceptible individuals include the source, purity, and formulation of the replacement product (eg, plasma-derived versus recombinant, full-length versus modified factor sequence, presence of von Willebrand factor [VWF] or other proteins) and the intensity of treatment (eg, dose, number of exposure days) [3]. The age at which factor replacement is initiated and switching products do not appear to have a major role in inhibitor development; however, the intensity of treatment, presence of danger signals, and use of prophylaxis may all influence the age at which treatment is started. (See 'Intensity of therapy (dose, schedule, number of exposure days)' below and 'External/environmental factors' below.)
Replacement product — There are a number of factor concentrates, including plasma-derived of various purities as well as recombinant products that contain various genetic sequences and/or sequence or other modifications to prolong half-life, and that are made with a number of different cell culture systems and purification protocols. Some plasma-derived products also contain VWF. No "best" factor replacement product that has all the optimal attributes for each patient. (See "Hemophilia A and B: Routine management including prophylaxis", section on 'Available products'.)
As each of the replacement products has become available at different times, and practices have varied over time and place, comparison with historical controls is especially difficult. There is only a single large randomized trial comparing different products, and no trial has compared all available products with each other.
The 2016 Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) trial remains the only prospective randomized trial comparing replacement products. SIPPET randomly assigned 264 children under the age of six years with severe hemophilia A (factor VIII <1 percent) and no or minimal previous factor therapy to receive a recombinant factor VIII product or a plasma-derived factor VIII product containing VWF, and followed them for up to 50 exposure days or three years after randomization, whichever came first [41]. The treatment regimen (prophylaxis versus on-demand) was at the discretion of the treating clinician. The primary outcome was development of any inhibitor with a titer of at least 0.4 Bethesda units (BU) using a centrally performed assay (Nijmegen method). Secondary outcomes included development of high titer inhibitors (≥5 BU).The majority of patients were enrolled from India, Egypt, and Iran, with smaller numbers from the United States, Italy, and other countries.
The peak timing of inhibitor development in SIPPET participants was during the first 15 exposure days. Inhibitors developed in a higher percentage of the those treated with the recombinant factor product (47 of 126 individuals who received recombinant factor VIII [37 percent] versus 29 of 125 individuals who received plasma-derived factor VIII with VWF [23 percent]; hazard ratio [HR] for recombinant products 1.87) [41]. The results remained essentially the same when analyzed after removing data on second-generation products, which previously had been suggested to have an increased risk of inhibitor development. High titer inhibitors were also more frequent in the recombinant factor VIII arm (24 versus 16 percent).
There were two deaths, both in the plasma-derived factor VIII with VWF arm (one from bleeding and one motor vehicle accident) and nine episodes of severe bleeding (six in the recombinant factor VIII arm and five in the plasma-derived factor VIII with VWF arm). The rate of prophylaxis (rather than on-demand therapy) was slightly higher in the recombinant factor VIII arm (55 versus 51 percent).
There has been great interest in determining the generalizability and clinical application of the SIPPET results, as noted by the study's authors, and various post-hoc analyses of different patient groups in the trial appear to show consistency with the original trial results [42]. A more challenging question is whether the results can be generalized to other recombinant factor products (eg, third-generation or extended half-life products, versus the specific first-, second-, and third-generation recombinant products used in the trial) [43]. The following conclusions seem reasonable:
●For all patients, the choice of product is complex and must balance a number of benefits, risks, and burdens. For those who require treatment with a factor replacement product for prophylaxis or treatment of bleeding, we individualize the choice of product based on the patient's circumstances and needs, following an open discussion with the patient regarding data on specific products and patient values and preferences.
●All inhibitors in the SIPPET trial occurred before 39 exposure days, and all high titer inhibitors occurred before 34 exposure days. Thus, for individuals with hemophilia A who are receiving a recombinant factor VIII product, who have not developed an inhibitor, and who are past the high-risk exposure period, switching to a VWF-containing plasma-derived product is not indicated.
●Analysis of each specific recombinant product used in the trial did not alter the initial findings [42]. However, the trial did not include some of the recombinant products that have subsequently become available, which appear to have an inhibitor rate that may approach that seen with factor VIII plus VWF-containing products. Thus, the decision to avoid exposure to recombinant products during the early phases of treatment requires a discussion between the family and provider.
The Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF) in the United States and the European Medicines Agency have not advocated a change to plasma-derived products based on the results of the SIPPET trial [44-46]. (See 'Society guideline links' below.)
The mechanism of increased risk of inhibitors with certain recombinant products is unknown. The plasma-derived products studied in the SIPPET trial contained VWF and other plasma proteins and are likely to differ in post-translational modifications from the recombinant products used in the trial, which were manufactured from non-human cell lines. It is possible that VWF may mask epitopes on the infused plasma-derived factor VIII or may protect factor VIII from endocytosis by antigen-presenting cells [47]. However, not all plasma-derived products contain VWF, and some recombinant products are made in human cell lines; the impact of these differences on inhibitor development is unknown.
Further trials using the newer-generation recombinant products made in human cell lines and those with extended half-lives are ongoing.
Prior to the SIPPET trial, information on inhibitor development with recombinant products was obtained in the 2013 Research Of Determinants of INhibitor development among previously untreated patients with haemophilia (RODIN) study, which prospectively evaluated 574 children with severe hemophilia A [48]. Inhibitors developed in 32 percent (high titer inhibitors in 22 percent). The risk of inhibitor formation was higher with second-generation full-length recombinant products compared with third-generation recombinant products (adjusted HR 1.60; 95% CI 1.08-2.37); however, the implications of this finding were less clear due to lack of randomization and small numbers of patients.
A 2012 observational study of 111 patients with hemophilia A who developed inhibitors found that compared with those who received low/intermediate-purity factor VIII products, those who received high-purity plasma-derived products had an increased risk of inhibitor development (adjusted HR 2.0; 95% CI 1.1-4.0) and those who received recombinant factor VIII had a higher rate of inhibitor development (adjusted HR 4.9; 95% CI 2.9-8.3) [49]. A 2018 observational study of 395 patients with severe hemophilia A from France (the FranceCoag cohort) found that inhibitor development was more likely in those who received one of two recombinant products compared with a plasma-derived product (cumulative incidence at 75 exposure days, 20 or 32 percent versus 13 percent) [50].
Some observational studies published before the SIPPET trial found no difference between recombinant and plasma-derived products; however, these results may have been subject to confounding factors that were eliminated in the randomized trial [51,52].
Intensity of therapy (dose, schedule, number of exposure days) — The dose and schedule at which the product is administered is reflected in the number of exposure days (days on which the patient received one or more factor infusions) (see 'Terminology and definitions' above), which is a strong predictor of inhibitor development.
●Hemophilia A – Inhibitors typically develop during the first 20 exposure days, as illustrated in the following studies:
•Severe disease – In the SIPPET trial (randomized trial of recombinant versus plasma-derived factor VIII in 264 children with severe hemophilia A), all inhibitors developed before exposure day 39, and 90 percent occurred before exposure day 20; for high titer inhibitors, all occurred before exposure day 34 and 90 percent before exposure day 16 [53].
In the FranceCoag cohort (395 children with severe hemophilia A), the median number of exposure days at inhibitor detection was 14, and the greatest percentage of inhibitors developed before exposure day 25 [50].
•Mild to moderate disease – In the INSIGHT study, inhibitor development was assessed in 1112 people with mild to moderate hemophilia A (factor VIII levels 2 to 40 units/dL) who were treated with factor VIII, 59 of whom developed inhibitors [54]. Of these, 41 (69 percent) developed an inhibitor before 50 exposure days, 17 (29 percent) developed an inhibitor between 50 and 100 exposure days, and one developed an inhibitor after 100 exposure days. The cumulative risk of inhibitor development was calculated as 5 percent at 28 exposure days, 7 percent at 50 exposure days, and 13 percent at 100 exposure days.
●Hemophilia B – There are fewer data to use in determining the correlation between the number of exposure days and inhibitor development in individuals with hemophilia B. In a review of the 88 patients in the international hemophilia B database, those who developed inhibitors did so at a median of 11 exposure days [55].
However, dose intensity is not simply the number of exposure days. As an example, dosing twice daily for three consecutive days after a serious bleed is more intense than dosing once every other day for three days of prophylaxis, yet both are counted as three exposure days. Thus, dose intensity may constitute a separate consideration over and above the number of exposure days. Dose intensity may be a better surrogate than exposure days for factors that affect the immune response, such as the degree of tissue injury. (See 'Patient characteristics' above and 'External/environmental factors' below.)
If an individual requires factor administration for surgery or to treat bleeding, factor should not be withheld to reduce the risk of inhibitor development. Data are conflicting regarding whether the risk of inhibitors changes with continuous infusion versus intermittent dosing. Some studies have suggested that continuous infusion increases inhibitor rate and others have suggested the opposite [56,57]. Thus, we do not favor or disfavor continuous infusion; we use the therapy that is deemed optimal for hemostasis for the specific patient. (See "Treatment of bleeding and perioperative management in hemophilia A and B".)
Age at which factor prophylaxis is initiated — The age at which factor replacement is initiated is challenging to separate from the severity of disease. Starting prophylaxis early may reduce inhibitor development, especially if there is ongoing exposure without danger signals (eg, repeated exposures in the absence of surgery, trauma, or spontaneous bleeding). However, this must be balanced with the burdens of routine intravenous therapy in a young infant or child. This paradigm may change with the introduction of emicizumab for hemophilia A. (See "Hemophilia A and B: Routine management including prophylaxis", section on 'Age of initiation and dosing schedule'.)
Although not addressed in a randomized trial, the effect of age at first treatment seems to be a marker for other risk factors rather than an independent risk factor for inhibitor development. Two studies demonstrated that age at first treatment did not correlate with inhibitor development after adjustment for other factors:
●In a case-control study involving 108 children with hemophilia A, there was a trend towards greater likelihood of inhibitor development when factor was started at a younger age (<11 months versus ≥11 months), but this trend was no longer present after adjusting for genetic factors [19].
●In the Concerted Action on Neutralizing Antibodies in severe hemophilia A (CANAL) study, which retrospectively investigated 366 patients with hemophilia A, the rate of inhibitor development appeared to correlate with age at first replacement therapy, but the effect disappeared after adjustment for treatment intensity [20].
Switching products — There are multiple studies that address the role of switching products in inhibitor development; none of these support an increased risk of inhibitor development due to switching products in previously treated patients [58-60]. As an example, in an observational study in which all patients with hemophilia A in Ireland (113 individuals) were switched from one recombinant factor VIII product to another, only one developed a new inhibitor; this was a one-year-old boy who had only received three doses of the previous product and was therefore at high risk for inhibitor development [61].
If antibodies form in multiply-exposed patients who have been changed to a new product, it is reasonable to investigate product-related factors [58,62,63]. In this case, consideration should be given to the use of the prior product if the patient has had many exposure days in the past, although change to the prior product may not always result in inhibitor disappearance.
External/environmental factors — Some studies have suggested that the degree of injury or tissue damage present at the time of factor infusion may contribute to the immune response to the factor (ie, the "danger theory") [3,64]. More severe injury is likely to accompany major bleeding and/or surgery. Investigators in the RODIN study used the dose of factor VIII as a surrogate for more severe injury and analyzed the rate of inhibitor development relative to the factor VIII dose intensity in a subset of previously unexposed children given factor VIII [65]. High-intensity factor treatment was associated with an increased risk of inhibitor development (adjusted HR 2.0; 95% CI 1.3-3.0), while prophylactic therapy was associated with a lower risk (adjusted HR 0.61; 95% CI 0.35-1.1).
While these findings suggest a potential biologic mechanism, they should not be interpreted to advocate the use of less intensive treatment of severe bleeding. Bleeding is treated with factor infusions or bypassing therapy, as discussed separately. (See "Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Acute therapy for bleeding'.)
Clinical trials are investigating the use of low-dose prophylactic factor infusions in the absence of danger signals as a means of reducing inhibitor development [66].
Several observational studies have found no correlation between administration of routine vaccinations (eg, influenza vaccine) and inhibitor development [19]. Preclinical studies suggest vaccinations may be associated with a lower risk of inhibitors [67].
Risk score (hemophilia A) — Data from a cohort of consecutive patients with severe hemophilia A in the CANAL study were used to develop a risk score for the development of factor VIII inhibitors based on three risk factors [68]:
●Family history of inhibitors – 2 points
●High-risk gene mutation – 2 points
●Intensive treatment at first bleeding episode – 3 points
In the initial study cohort (332 patients), inhibitor incidences for individuals with risk scores of 0, 2, or ≥3 points were 6, 23, and 57 percent, respectively. Similar incidences were noted in a validation cohort of 64 patients. Of note, this score requires that the patient be treated, a disadvantage when trying to predict the risk of inhibitor development in individuals who have not been exposed to exogenous factor VIII.
EPIDEMIOLOGYInhibitors are more common in hemophilia A than in hemophilia B, with overall prevalence in individuals with severe disease as follows:
●Hemophilia A – Approximately 20 to 30 percent [69-75]
●Hemophilia B – Approximately 1.5 to 3 percent [28,55,70,71,76]
The incidence of inhibitors is highest in individuals with severe disease during the first 50 factor exposure days, although individuals with mild to moderate disease can also develop inhibitors. It has been hypothesized that the presence of some circulating factor IX in most people with hemophilia B may result in a greater likelihood of immune tolerance and may partially explain the lower prevalence of inhibitors [55].
Certain groups such as blacks have higher inhibitor rates (up to 50 percent in those with severe hemophilia A and 5 percent of those with severe hemophilia B) [28,77]. (See 'Predisposing influences' above.)
TYPICAL PRESENTATIONIn some cases, especially in hemophilia A, an inhibitor may be clinically silent and may not lead to a marked increase in the frequency or severity of bleeding; inhibitors may be identified when the response to infused factor is inadequate (ie, when there is no increase in factor activity after factor infusion and/or bleeding does not cease with factor infusion). In a prospective surveillance study in the United States that enrolled 1163 individuals with hemophilia A or B, 23 new factor VIII inhibitors were identified, and of these, 14 (61 percent) were clinically silent [78]. These data underscore the need for ongoing routine inhibitor surveillance in hemophilia. (See 'Routine screening and preoperative testing' below.)
However, a patient receiving prophylactic factor infusions who develops an inhibitor may experience new breakthrough bleeding or may have poor or delayed resolution of bleeding. Patients with inhibitors may also have altered pharmacokinetics of the replacement factor, which may result in impaired hemostasis and an increased rate of musculoskeletal complications. Over time, inhibitors alter the disease course, as affected individuals have poorly controlled joint bleeding and develop target joints, with subsequent increased bleeding in these joints due to acute and chronic synovitis [79]. An inhibitor should be suspected when any bleeding episode is refractory to usual therapy, particularly in patients with severe hemophilia.
Individuals with mild or moderate hemophilia (factor activity between 1 and 40 percent) who develop inhibitors that crossreact with their endogenous factor may be converted to a more severe state. One series identified factor VIII inhibitors in 26 patients with mild or moderate hemophilia A; most of the inhibitors developed after a period of intensive replacement therapy [25]. Spontaneous bleeding occurred in 22, with a bleeding pattern similar to that of acquired hemophilia in 17.
High titer inhibitors typically rise at approximately five to seven days after exposure to factor, peak at 7 to 21 days, and may persist for years, even in the absence of re-exposure [80,81].
Individuals who develop inhibitors may have an infusion reaction in response to factor administration, although this is uncommon in hemophilia A. More commonly in hemophilia B, individuals who develop inhibitors may have other manifestations such as allergic-type reactions or anaphylaxis to factor infusions, and/or nephrotic syndrome during immune tolerance induction (ITI). (See 'Immune tolerance induction' below.)
SCREENING AND EARLY DIAGNOSISEarly detection of inhibitors is important, both to be aware of the inhibitor when selecting products to treat bleeding, as well as to facilitate early consideration of inhibitor eradication or switching to a different product for prophylaxis. These decisions are discussed separately. (See "Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Inhibitors' and "Hemophilia A and B: Routine management including prophylaxis", section on 'Overview of decision-making'.)
Routine screening and preoperative testing — Experts generally agree that individuals should be screened periodically for inhibitors and tested for inhibitors prior to surgery and/or if factor infusions do not produce the expected increase in factor levels. Surveillance is a best practice approach because in many cases it is the only way to determine whether an inhibitor has developed. Guidance has been provided by the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), which recommends surveillance and testing for inhibitors as follows [40]:
●Hemophilia A – For severe disease, at least every third exposure day or every three months (whichever is sooner) until 20 exposure days have been reached; then every three to six months until 150 exposure days have been reached. For individuals receiving prophylaxis, it may be more practical to measure the trough factor level every three to six months from exposure day 20 until 150 exposure days and only test for an inhibitor if the trough factor level is lower than expected. After exposure day 150, inhibitor testing should continue one to two times per year indefinitely.
For moderate or mild disease, test annually if exposed to factor as well as after any intensive factor exposure (eg, at least five exposure days) or after any surgery. More intensive surveillance may be appropriate if there is a factor VIII mutation with an especially high inhibitor prevalence. (See 'Patient characteristics' above.)
●Hemophilia B – For severe disease, at least every third exposure day or every three months (whichever is sooner) until 20 exposure days have been reached; then every three to six months until 150 exposure days have been reached. After exposure day 150, inhibitor testing is not needed unless clinically indicated; no factor IX inhibitors have been reported beyond exposure day 150. Some experts may change the cutoff to exposure day 50, as few factor IX inhibitors emerge beyond 50 exposure days.
A 2015 United States guideline from the International Immune Tolerance Induction Study Investigators and 2015 guidance from the National Hemophilia Foundation (NHF) Medical and Scientific Advisory Council (MASAC) concur with this approach to inhibitor screening [82,83].
These guidelines also note that additional inhibitor testing is appropriate in individuals with hemophilia A or B in selected circumstances such as the following:
●Before elective procedures that may require factor administration
●If the clinical or laboratory response to factor infusion is suboptimal
●If the patient has an infusion reaction or allergic reaction to factor administration
●If the patient has an increase in bleeding manifestations (increased severity or frequency of bleeding)
While not addressed by guidelines, it is also important to monitor inhibitor titers in individuals with hemophilia A with inhibitors who are receiving emicizumab prophylaxis, especially before elective surgery. This is because inhibitor titers in these individuals may decline to undetectable levels, in which case there is a window during which factor infusions can be used to treat or prevent bleeding. Typically, there is an approximately five- to seven-day window before the anamnestic immune response occurs and the inhibitor titer rises. (See "Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A'.)
A 2015 expert report from the Centers for Disease Control (CDC) in the United States stated that inhibitors are generally under-reported [84]. In an analysis of 12,851 people with hemophilia in the Universal Data Collection surveillance system, only 39 percent of the data forms indicated that inhibitor testing had been performed (average of 46 percent for those with severe hemophilia).
Inhibitor diagnosis and characterization (titer) — Inhibitors may be detected on routine screening, preoperative testing, or testing for a clinical indication such as inadequate response or allergic reaction to factor infusion, as discussed above. (See 'Routine screening and preoperative testing' above.)
Ideally, inhibitor assays are done after a washout of infused factor, when the individual is at their baseline factor level (eg, at least 48 hours after the last dose of factor VIII or 72 hours after the last dose of factor IX for standard half-life products; longer for extended half-life products) or at the trough before the next factor dose [1,40]. This is because infused factor may mask or quench a low titer inhibitor.
The diagnosis of an inhibitor is made using a Bethesda assay, which both identifies the inhibitor and quantifies it. The assay principle uses serial dilutions of patient plasma incubated at 37ºC with pooled normal plasma and measures factor activity using an activated partial thromboplastin time (aPTT)-based assay [85]. Typically, the Nijmegen modification is used (ie, the Nijmegen-Bethesda assay [NBA]); the NBA is considered the gold standard for inhibitor testing [1]. The Nijmegen modification further standardizes the pH and protein concentrations in the assay, which improves specificity and reliability, especially at low inhibitor titers [86,87].
Importantly, this type of aPTT-based assay cannot be used to diagnose or quantify inhibitors in individuals receiving emicizumab. Emicizumab will normalize the aPTT despite the presence of an inhibitor, making it appear that the inhibitor is absent or of markedly lower titer than it actually is. For individuals receiving emicizumab, inhibitor titer must be measured with a chromogenic assay specific for factor VIIIa activity, similar to testing factor VIII levels on emicizumab. (See "Hemophilia A and B: Routine management including prophylaxis", section on 'Emicizumab for hemophilia A' and "Treatment of bleeding and perioperative management in hemophilia A and B".)
The titer of the inhibitor, expressed as Bethesda units (BU), is the reciprocal dilution of patient plasma that results in residual 50 percent factor activity. Thus, an individual with a titer of 20 BU requires 20 serial plasma dilutions to dilute out the inhibitor sufficiently to result in 50 percent activity from the normal plasma. An individual with a titer of 2 BU requires only two serial dilutions (ie, their inhibitor is lower).
●A titer of ≥5 BU is considered a high titer inhibitor. Inhibitors that have demonstrated a high titer are considered high-responding inhibitors, even if the titer subsequently declines below 5 BU.
●A titer <5 BU despite repeated exposures to factor is considered a low-responding inhibitor.
An elevated inhibitor titer (typically defined as a level ≥0.6 BU per mL) should be confirmed promptly with a second sample, especially if the first sample was drawn through a heparinized line [1].
Sources of test interference in Bethesda assays include other antibodies such as a lupus anticoagulant (LA; an antibody that reacts with phospholipids in the clot-based assay and prolongs the aPTT). If testing reveals an LA, pharmacokinetic studies and serial testing over time may help determine whether a specific factor VIII inhibitor is also present [88]. Close consultation with the coagulation laboratory is important to ensure that appropriate testing is performed. (See "Diagnosis of antiphospholipid syndrome", section on 'Antiphospholipid antibody testing'.)
Alternative approaches to inhibitor testing and quantification that use immunoassays to detect antibodies to factor are under development but are not in clinical use [89].
Communication of inhibitor status — It is crucial for clinicians caring for people with hemophilia to have current access to the latest information about their inhibitor status. If an individual with an inhibitor has serious bleeding (spontaneous or traumatic) or requires surgery, the details of their inhibitor status will determine pathways for management. Provision of a wallet card (available through a hemophilia treatment center) with accurate information and/or contact information for the individual's primary hemophilia caregiver facilitates provision of this information to people who do not have immediate access to the latest medical record information for the person with hemophilia.
In the United States, development of a new inhibitor should be reported to the US Food and Drug Administration MedWatch adverse event reporting system.
==Genes affected in Hemophilia==
*Changes in the ''F8'' [[gene]] are responsible for hemophilia A, while mutations in the ''F9'' gene cause hemophilia B. The ''F8'' gene provides instructions for making a protein called coagulation [[factor VIII]]. A related protein, coagulation [[factor IX]], is produced from the ''F9'' gene. Coagulation factors are proteins that work together in the blood clotting process. After an injury, blood clots protect the body by sealing off damaged blood vessels and preventing excessive blood loss.
*Mutations in the ''F8'' or ''F9'' gene lead to the production of an abnormal version of coagulation factor VIII or coagulation factor IX, or reduce the amount of one of these proteins. The altered or missing protein cannot participate effectively in the blood clotting process. As a result, blood clots cannot form properly in response to injury. These problems with blood clotting lead to continuous bleeding that can be difficult to control. The mutations that cause severe hemophilia almost completely eliminate the activity of coagulation factor VIII or coagulation factor IX. The mutations responsible for mild and moderate hemophilia reduce but do not eliminate the activity of one of these proteins.
*Another form of the disorder, known as [[acquired]] hemophilia, is not caused by inherited gene mutation. This rare condition is characterized by abnormal bleeding into the skin, muscles, or other soft tissues, usually beginning in adulthood. Acquired hemophilia results when the body makes specialized proteins called auto antibodies that attack and disable coagulation factor VIII. The production of auto antibodies is sometimes associated with pregnancy, immune system disorders, cancer, or allergic reactions to certain drugs. In about half of cases, the cause of acquired hemophilia is unknown.<ref>{{Cite web | title = NIH Hemophilia Pathophysiology| url =http://ghr.nlm.nih.gov/condition/hemophilia }}</ref>
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 14:27, 2 August 2019


https://https://www.youtube.com/watch?v=nkC1vZaUpxs%7C350}}

Hemophilia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemophilia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemophilia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia pathophysiology

CDC on Hemophilia pathophysiology

Hemophilia pathophysiology in the news

Blogs on Hemophilia pathophysiology

Directions to Hospitals Treating Hemophilia

Risk calculators and risk factors for Hemophilia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]Fahd Yunus, M.D. [3]

Overview

Hemophilia is a genetic bleeding disorder resulting from the insufficient levels of clotting factors in the body. The clotting factors irregularity causes a lack of clumping of blood required to form a clot to plug a site of a wound. The genes involved in the pathogenesis of hemophilia include the F8 gene in hemophilia A, F9 gene in hemophilia B, and F11 gene in C. Hemophilia predominantly affects the male population but the sub-type hemophilia C, with an autosomal inheritance pattern, can affect the males as well as females.

Pathophysiology

Physiology

The normal physiology of hemostasis can be summarized as follows:

1. Primary hemostasis

2. Secondary hemostasis

3. Fibrinolysis

Cell-Based Model of Coagulation

a. Initiation

b. Amplification

c. Propagation

Pathogenesis

  • Mild (factor level > 0.05–0.40 IU/mL)
  • Moderate (factor level = 0.01–0.05 IU/mL)
  • Severe (factor level < 0.01 IU/mL)

Hemophilia A

  1. Classic mutations in the F8 gene that cause structural changes in the FVIII molecule or even produce a truncated protein lacking essential functional domains.[18][19]
  2. Mutations in proteins that interact intracellularly in the correct folding and trafficking of the FVIII protein or mutations in extracellular plasma proteins such as von Willebrand factor (VWF).[20][21][22][23]
  3. The third category encompasses patients who have the clinical disease but have no mutations in the F8 gene or in any of the known interacting partners.[16]

Hemophilia B

Hemophilia C

Genetics

Hemophilia A

Hemophilia B

Hemophilia C

Associated Conditions

  • Hemophilia can be associated with the following conditions:

Gross Pathology

On gross pathology, hemophilia is characterized by the following findings:

Microscopic Pathology

On microscopic histopathological analysis, hemophilia can be characterized by the following findings:

References

  1. ↑ Lippi G, Favaloro EJ, Franchini M, Guidi GC (February 2009). "Milestones and perspectives in coagulation and hemostasis". Semin. Thromb. Hemost. 35 (1): 9–22. doi:10.1055/s-0029-1214144. PMID 19308889.
  2. ↑ Lippi G, Franchini M, Guidi GC (2007). "Diagnostic approach to inherited bleeding disorders". Clin. Chem. Lab. Med. 45 (1): 2–12. doi:10.1515/CCLM.2007.006. PMID 17243907.
  3. ↑ Favaloro, Emmanuel (2017). Hemostasis and thrombosis : methods and protocols. New York: Humana Press Springer. ISBN 9781493971961.
  4. ↑ Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB (October 2006). "Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor". J. Thromb. Haemost. 4 (10): 2103–14. doi:10.1111/j.1538-7836.2006.02146.x. PMID 16889557.
  5. ↑ Yee A, Kretz CA (February 2014). "Von Willebrand factor: form for function". Semin. Thromb. Hemost. 40 (1): 17–27. doi:10.1055/s-0033-1363155. PMID 24338608.
  6. ↑ Favaloro, Emmanuel (2017). Hemostasis and thrombosis : methods and protocols. New York: Humana Press Springer. ISBN 9781493971961.
  7. ↑ Favaloro, Emmanuel (2017). Hemostasis and thrombosis : methods and protocols. New York: Humana Press Springer. ISBN 9781493971961.
  8. ↑ Kwaan H, Lisman T, Medcalf RL (March 2017). "Fibrinolysis: Biochemistry, Clinical Aspects, and Therapeutic Potential". Semin. Thromb. Hemost. 43 (2): 113–114. doi:10.1055/s-0036-1598000. PMID 28253534.
  9. ↑ 9.0 9.1 Hoffman, Maureane (2003). "A cell-based model of coagulation and the role of factor VIIa". Blood Reviews. 17: S1–S5. doi:10.1016/S0268-960X(03)90000-2. ISSN 0268-960X.
  10. ↑ Favaloro, Emmanuel (2017). Hemostasis and thrombosis : methods and protocols. New York: Humana Press Springer. ISBN 9781493971961.
  11. ↑ Favaloro, Emmanuel (2017). Hemostasis and thrombosis : methods and protocols. New York: Humana Press Springer. ISBN 9781493971961.
  12. ↑ Bonar RA, Lippi G, Favaloro EJ (2017). "Overview of Hemostasis and Thrombosis and Contribution of Laboratory Testing to Diagnosis and Management of Hemostasis and Thrombosis Disorders". Methods Mol. Biol. 1646: 3–27. doi:10.1007/978-1-4939-7196-1_1. PMID 28804815.
  13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 Mannucci PM, Tuddenham EG (June 2001). "The hemophilias--from royal genes to gene therapy". N. Engl. J. Med. 344 (23): 1773–9. doi:10.1056/NEJM200106073442307. PMID 11396445.
  14. ↑ 14.0 14.1 14.2 Bolton-Maggs, Paula HB; Pasi, K John (2003). "Haemophilias A and B". The Lancet. 361 (9371): 1801–1809. doi:10.1016/S0140-6736(03)13405-8. ISSN 0140-6736.
  15. ↑ 15.0 15.1 Berntorp E, Shapiro AD (April 2012). "Modern haemophilia care". Lancet. 379 (9824): 1447–56. doi:10.1016/S0140-6736(11)61139-2. PMID 22456059.
  16. ↑ 16.0 16.1 16.2 Oldenburg, Johannes; El-Maarri, Osman (2006). "New Insight into the Molecular Basis of Hemophilia A". International Journal of Hematology. 83 (2): 96–102. doi:10.1532/IJH97.06012. ISSN 0925-5710.
  17. ↑ Roosendaal G, Lafeber FP (July 2006). "Pathogenesis of haemophilic arthropathy". Haemophilia. 12 Suppl 3: 117–21. doi:10.1111/j.1365-2516.2006.01268.x. PMID 16684006.
  18. ↑ Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ (February 1997). "Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins". J. Biol. Chem. 272 (7): 4327–34. PMID 9020152.
  19. ↑ Pipe SW, Morris JA, Shah J, Kaufman RJ (April 1998). "Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin". J. Biol. Chem. 273 (14): 8537–44. PMID 9525969.
  20. ↑ Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D (April 1998). "Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII". Cell. 93 (1): 61–70. PMID 9546392.
  21. ↑ Zhang B, Cunningham MA, Nichols WC, Bernat JA, Seligsohn U, Pipe SW, McVey JH, Schulte-Overberg U, de Bosch NB, Ruiz-Saez A, White GC, Tuddenham EG, Kaufman RJ, Ginsburg D (June 2003). "Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex". Nat. Genet. 34 (2): 220–5. doi:10.1038/ng1153. PMID 12717434.
  22. ↑ Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D (October 1989). "New variant of von Willebrand disease with defective binding to factor VIII". Blood. 74 (5): 1591–9. PMID 2506947.
  23. ↑ Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C (August 1991). "Identification of two point mutations in the von Willebrand factor gene of three families with the 'Normandy' variant of von Willebrand disease". Br. J. Haematol. 78 (4): 506–14. PMID 1832934.
  24. ↑ Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM (July 2017). "Acquired hemophilia A: Updated review of evidence and treatment guidance". Am. J. Hematol. 92 (7): 695–705. doi:10.1002/ajh.24777. PMID 28470674.
  25. ↑ 25.0 25.1 25.2 25.3 25.4 Yang F, Zhou YS, Jia Y (December 2018). "[Systemic lupus erythematosus with acquired hemophilia A: a case report]". Beijing Da Xue Xue Bao (in Chinese). 50 (6): 1108–1111. PMID 30562791.
  26. ↑ Castaman, G.; Bonetti, E.; Messina, M.; Morfini, M.; Rocino, A.; Scaraggi, F. A.; Tagariello, G. (2013). "Inhibitors in haemophilia B: the Italian experience". Haemophilia. 19 (5): 686–690. doi:10.1111/hae.12158. ISSN 1351-8216.
  27. ↑ Goodeve AC (July 2015). "Hemophilia B: molecular pathogenesis and mutation analysis". J. Thromb. Haemost. 13 (7): 1184–95. doi:10.1111/jth.12958. PMC 4496316. PMID 25851415.
  28. ↑ 28.0 28.1 Chitlur M, Warrier I, Rajpurkar M, Lusher JM (September 2009). "Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)". Haemophilia. 15 (5): 1027–31. doi:10.1111/j.1365-2516.2009.02039.x. PMID 19515028.
  29. ↑ 29.0 29.1 Shearin-Patterson T, Davidson E (April 2013). "Hemophilia C". JAAPA. 26 (4): 50. PMID 23610841.
  30. ↑ 30.0 30.1 Duga S, Salomon O (September 2013). "Congenital factor XI deficiency: an update". Semin. Thromb. Hemost. 39 (6): 621–31. doi:10.1055/s-0033-1353420. PMID 23929304.
  31. ↑ 31.0 31.1 Bolton-Maggs PH (2009). "Factor XI deficiency--resolving the enigma?". Hematology Am Soc Hematol Educ Program: 97–105. doi:10.1182/asheducation-2009.1.97. PMID 20008187.
  32. ↑ Wheeler AP, Gailani D (July 2016). "Why factor XI deficiency is a clinical concern". Expert Rev Hematol. 9 (7): 629–37. doi:10.1080/17474086.2016.1191944. PMID 27216469.
  33. ↑ 33.0 33.1 33.2 Kadir RA, Economides DL, Lee CA (January 1999). "Factor XI deficiency in women". Am. J. Hematol. 60 (1): 48–54. PMID 9883805.
  34. ↑ Asakai R, Chung DW, Davie EW, Seligsohn U (July 1991). "Factor XI deficiency in Ashkenazi Jews in Israel". N. Engl. J. Med. 325 (3): 153–8. doi:10.1056/NEJM199107183250303. PMID 2052060.
  35. ↑ Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, Bochicchio RA, Ferrara G, Guarini A, Foà R, Mazzucconi MG (July 2015). "Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre". Haemophilia. 21 (4): 496–501. doi:10.1111/hae.12628. PMID 25623511.
  36. ↑ Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN (March 1985). "Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds". Blood. 65 (3): 719–24. PMID 3871646.
  37. ↑ Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG (February 1995). "Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study". Thromb. Haemost. 73 (2): 194–202. PMID 7792729.
  38. ↑ Lakich, Delia; Kazazian, Haig H.; Antonarakis, Stylianos E.; Gitschier, Jane (1993). "Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A". Nature Genetics. 5 (3): 236–241. doi:10.1038/ng1193-236. ISSN 1061-4036.
  39. ↑ Bagnall, R. D. (2002). "Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A". Blood. 99 (1): 168–174. doi:10.1182/blood.V99.1.168. ISSN 0006-4971.
  40. ↑ Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM (1984). "Characterization of the human factor VIII gene". Nature. 312 (5992): 326–30. PMID 6438525.
  41. ↑ 41.0 41.1 Lannoy, N.; Abinet, I.; Dahan, K.; Hermans, C. (2009). "Identification ofde novodeletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency". Haemophilia. 15 (3): 797–801. doi:10.1111/j.1365-2516.2008.01974.x. ISSN 1351-8216.
  42. ↑ 42.0 42.1 42.2 Peyvandi, Flora; Garagiola, Isabella; Young, Guy (2016). "The past and future of haemophilia: diagnosis, treatments, and its complications". The Lancet. 388 (10040): 187–197. doi:10.1016/S0140-6736(15)01123-X. ISSN 0140-6736.
  43. ↑ Davie EW, Fujikawa K (1975). "Basic mechanisms in blood coagulation". Annu. Rev. Biochem. 44: 799–829. doi:10.1146/annurev.bi.44.070175.004055. PMID 237463.
  44. ↑ Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K (July 1985). "Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)". Biochemistry. 24 (14): 3736–50. PMID 2994716.
  45. ↑ Asakai R, Chung DW, Ratnoff OD, Davie EW (October 1989). "Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations". Proc. Natl. Acad. Sci. U.S.A. 86 (20): 7667–71. PMC 298131. PMID 2813350.
  46. ↑ Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J (July 2015). "Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study". Haemophilia. 21 (4): 481–9. doi:10.1111/hae.12655. PMC 4657494. PMID 25817556.
  47. ↑ Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A (September 2002). "End-stage liver disease in persons with hemophilia and transfusion-associated infections". Blood. 100 (5): 1584–9. PMID 12176875.
  48. ↑ Qvigstad C, Tait RC, Rauchensteiner S, Berntorp E, de Moerloose P, Schutgens RE, Holme PA (September 2018). "The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment". Medicine (Baltimore). 97 (39): e12551. doi:10.1097/MD.0000000000012551. PMC 6181599. PMID 30278553.
  49. ↑ Pathirana UG, Gunawardena N, Abeysinghe H, Copley HC, Somarathne MG (December 2014). "Acquired haemophilia A associated with autoimmune thyroiditis: a case report". J Med Case Rep. 8: 469. doi:10.1186/1752-1947-8-469. PMC 4320580. PMID 25547669.
  50. ↑ Narazaki T, Haji S, Nakashima Y, Tsukamoto Y, Tsuda M, Takamatsu A, Ohno H, Matsushima T, Matsumoto T, Nogami K, Shima M, Shiratsuchi M, Ogawa Y (September 2018). "Acquired hemophilia A associated with autoimmune pancreatitis with serum IgG4 elevation". Int. J. Hematol. 108 (3): 335–338. doi:10.1007/s12185-018-2441-3. PMID 29582334.
  51. ↑ Mulliez SM, Vantilborgh A, Devreese KM (June 2014). "Acquired hemophilia: a case report and review of the literature". Int J Lab Hematol. 36 (3): 398–407. doi:10.1111/ijlh.12210. PMID 24750687.
  52. ↑ Shetty S, Sharma N, Ghosh K (March 2016). "Epidemiology of hepatocellular carcinoma (HCC) in hemophilia". Crit. Rev. Oncol. Hematol. 99: 129–33. doi:10.1016/j.critrevonc.2015.12.009. PMID 26754251.
  53. ↑ Barg AA, Livnat T, Kenet G (March 2017). "An extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A". Thromb. Res. 151 Suppl 1: S82–S85. doi:10.1016/S0049-3848(17)30074-9. PMID 28262242.
  54. ↑ Makris M, Konkle BA (March 2017). "Hepatitis C in haemophilia: time for treatment for all". Haemophilia. 23 (2): 180–181. doi:10.1111/hae.13183. PMID 28300362.
  55. ↑ Kasper CK (March 2004). "AIDS, hepatitis and hemophilia". J. Thromb. Haemost. 2 (3): 516–8. PMID 15009473.
  56. ↑ Goodman, Catherine (2015). Pathology : implications for the physical therapist. St. Louis, Missouri: Elsevier Saunders. ISBN 9781455745913.
  57. ↑ Murphy N, O'Mahony B, Flanagan P, Noone D, White B, Bergin C, Norris S, Thornton L (September 2017). "Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era". Haemophilia. 23 (5): 712–720. doi:10.1111/hae.13244. PMID 28752601.
  58. ↑ Eldash HH, Atwa ZT, Saad MA (January 2017). "Vitamin D deficiency and osteoporosis in hemophilic children: an intermingled comorbidity". Blood Coagul. Fibrinolysis. 28 (1): 14–18. doi:10.1097/MBC.0000000000000519. PMID 26825623.
  59. ↑ Albayrak C, Albayrak D (April 2015). "Vitamin D levels in children with severe hemophilia A: an underappreciated deficiency". Blood Coagul. Fibrinolysis. 26 (3): 285–9. doi:10.1097/MBC.0000000000000237. PMID 25485786.
  60. ↑ Cano LM, Quesada H, García-Alhama J, Cardona P (August 2013). "[Acquired haemophilia associated to myasthenia gravis]". Med Clin (Barc) (in Spanish; Castilian). 141 (4): 185–6. doi:10.1016/j.medcli.2012.12.005. PMID 23395131.
  61. ↑ Saini AG, Goswami JN, Suthar R, Sankhyan N, Vyas S, Singhi P (February 2017). "Probable Moyamoya Syndrome in Association with Hemophilia A in an Infant". Indian J Pediatr. 84 (2): 164–165. doi:10.1007/s12098-016-2229-5. PMID 27638653.
  62. ↑ 62.0 62.1 Kimura H, Uegaki M, Aoyama T, Miyoshi T, Nagai K, Hashimura T (May 2013). "[Acquired hemophilia presenting as gross hematuria and perineal subcutaneous hemorrhage after prostate biopsy: a case report]". Hinyokika Kiyo (in Japanese). 59 (5): 305–8. PMID 23719140.
  63. ↑ Maesako, Yoshitomo; Shimomura, Daiki; Ohno, Hitoshi (2013). "Acquired hemophilia A". Tenri Medical Bulletin. 16 (2): 133–135. doi:10.12936/tenrikiyo.16-015. ISSN 1344-1817.
  64. ↑ Centers for Disease Control and Prevention. Hemophilia Diagnosis. http://www.cdc.gov/ncbddd/hemophilia/diagnosis.html

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Hemophilia_pathophysiology&oldid=1578160"